BioSpace News Archive

KromaTiD, a single-cell analysis company focused on the research, development, and commercialization of technology solutions for the cell and gene therapy market, announces the launch of their dGH™ Cell Prep Kit for use in their dGH in-Site™ and dGH SCREEN™ assays.

In their commitment to helping startups get to commercialization and translate their discoveries and knowledge into products and services that make life better, Titan Bioplastics has received foundational support and funding from Spartan Innovations and Red Cedar Ventures.

Altamira Therapeutics (“Altamira” or the “Company”) (NASDAQ: CYTO) a company dedicated to developing therapeutics that address important unmet medical needs, today announced the publication of a peer-reviewed article in the scientific journal Pharmaceutics.

Idorsia Pharmaceuticals, U.S. Inc, today announced its partnership with Lindsey Vonn, world champion skier, philanthropist, entrepreneur and insomnia patient as an ambassador for QUVIVIQ™ (daridorexant) CIV.

Brand Institute is proud to announce its work with Duchesnay in developing the brand name PHEBURANE®.

Artelo Biosciences, Inc. today announced the completion of enrollment of the first three cohorts in the Cancer Appetite Recovery Study (CAReS) and the initiation of a fourth cohort expected to complete the first stage of the Phase 1b clinical trial.

Vector Laboratories , the pioneer of innovative proteomic and glycomic solutions, today announced the launch of its novel product Glysite™ Scout Glycan Screening Kits.

Paragonix Technologies , the leading hypothermic organ preservation provider, announced today its expanded enrollment in its GUARDIAN series of clinical registries aimed at investigating the impact of organ preservation.

Gb Sciences is a plant-inspired, biopharmaceutical research and drug development company that began building its proprietary digital research and analytics platform long before the pandemic sparked a digital transformation.

ScreenPro Security Inc. (CSE: SCRN) (OTCQB: SCRSF) (“ScreenPro” or the “Company”) is pleased to announce its monthly COVID-19 testing operations have increased by 10% since January 2022. The Company started its year with approximately 19,000 tests administered and has now reached approximately 21,000 tests in June 2022.